Japanese researchers used a nonviral piggyBac system to genetically modify cynomolgus monkeys, enabling more accurate disease ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form.

Researchers at University of Tsukuba have developed "tomoseqr"—a new software tool that enables easy estimation of the ...

Genetic engineering in non-human primates has historically faced limitations due to the reliance on virus-based gene delivery methods.

A recent study has shed light on the transcriptional regulatory mechanisms of Penicillium expansum, the fungal culprit behind ...

WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

Genetic engineering in non-human primates has long been limited by the need for virus-based gene delivery methods. Recently, ...

Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...

Genetic engineering in non-human primates has long been limited by the need for virus-based gene delivery methods. Recently, ...